Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis

There is a scarcity of data exploring the benefits of adjuvant or neoadjuvant chemotherapy in the treatment of breast cancer in older women. We used data from the National Cancer Database, a joint project of the Commission on Cancer and the American College of Surgeons. Between Jan 1, 2004, and Dec 31, 2014, 16 062 women with triple-negative breast cancer in the database met the inclusion criteria.

Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial

EORTC 22922/10925 was a randomized, phase 3 trial done across 46 radiation oncology departments from 13 countries. 15-year follow-up of 554 patients in the IM-MS irradiation group and 569 in the control group had died. Overall survival was 73% in the irradiated group.

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

Lung-MAP (S1400) was created to establish an infrastructure for biomarker screening and rapid regulatory intent evaluation of targeted therapies. Eligible patients were aged 18 years or older, had stage IV or recurrent squamous non-small-cell lung cancer. Median overall survival was 5.9 months for the targeted therapy groups, 7.7 months for docetaxel groups.

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

DANUBE is an open-label, randomised, controlled, phase 3 trial in patients with untreated, unresectable, locally advanced or metastatic urothelial carcinoma. Patients were randomly assigned to receive durvalumab monotherapy, tremelimumab or standard-of-care chemotherapy. Overall survival was compared between the monotherapy and chemotherapy groups.

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

The study compared pembrolizumab plus axitinib and sunitinIB for advanced renal cell carcinoma. Median follow-up of 30.6 months showed continued clinical benefit. Results continue to support the first-line treatment as the standard of care.

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

PANORAMA 3 is an open-label, randomized, phase 2 study being done at 71 sites across 21 countries. Patients aged 18 years or older with relapsed or relapsed and refractory multiple myeloma were randomly assigned. The overall response rate was highest in the 20 mg three times weekly and 20 mg twice weekly groups.

Deep learning model for the prediction of microsatellite instability in colorectal cancer: a diagnostic study

Detecting microsatellite instability (MSI) in colorectal cancer is crucial for clinical decision-making. Universal MSI testing is recommended, but many patients remain untested. We investigate the potential of a deep learning-based system for automated MSI prediction.

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

Combining an agonistic CD40 monoclonal antibody with chemotherapy induces T-cell-dependent tumor regression in mice and improves survival. The study was done at seven academic hospitals in the USA. Eligible patients were adults aged 18 years and older with untreated metastatic pancreatic adenocarcinoma.

Departments

Recent Posts